Immunosuppressive therapy for myelodysplastic syndromes: Refining the indications

Current Hematologic Malignancy Reports

Volumn 3, Issue 1, 2008, Pages 23-28

  Barrett, A John ^a   Sloand, Elaine M ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; ETANERCEPT; HLA DR15 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; LENALIDOMIDE; PEPTIDE VACCINE; PROTEIN PR1; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; WT1 PROTEIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CANCER IMMUNIZATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOKINE PRODUCTION; CYTOPENIA; DRUG INHIBITION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FOLLOW UP; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROPATHY; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW; SURVIVAL; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 41849113445     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0005-y     Document Type: Review

References (26)

1. Barrett J, Saunthararajah Y, Molldrem J: Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000, 37:15-29.
2. Barrett AJ, Sloand E, Young NS: Immunological mechanisms and treatment of MDS. In Myelodysplastic Syndromes: Clinical and Biological Advances. Edited by Greenberg PL. New York: Cambridge University Press; 2006. A comprehensive, topical review of the immunologic abnormalities contributing to MDS pathophysiology.
3. Chen G, Zheng W, Miyazato A: Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004, 104:4210-4218.
4. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al.: Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T cell receptor Vbeta profiles. Br J Haematol 1998, 102:1314-1322.
5. Young NS, Barrett AJ: Perspective: the treatment of severe acquired aplastic anemia. Blood 1995, 85:3367-3377.
6. Jonasova A, Neuwirtova R, Cermak J, et al.: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 100:304-309.
7. Molldrem JJ, Caples M, Mavroudis DA, et al.: Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699-705.
8. Sloand EM, Mainwaring L, Fuhrer M, et al.: Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851. A potential mechanism is described for clonal dominance of MDS stem cell clones that survive immune attack by being in an incomplete state of apoptosis.
9. Shimamoto T, Tohyama K, Okamoto T, et al.: Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 2003, 27:783-788.
10. Atoyebi W, Bywater L, Rawlings L, et al.: Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol 2002, 24:211-214.
11. Scheinberg P, Fischler S, Li L, et al.: Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007, 109:3219-3224.
12. Molldrem JJ, Leifer E, Bahceci E, et al.: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002, 137:156-163.
13. Aivado M, Rong A, Stadler M, et al.: Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002, 68:210-216.
14. Steensma DP, Dispenzieri A, Moore SB, et al.: Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003, 101:2156-2158.
15. Stadler M, Germing U, Kliche JO, et al.: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460-465.
16. Yazji S, Giles J, Tsimberidou AM, et al.: Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003, 17:2101-2106.
17. Killick SB, Mufti G, Cavenagh JD, et al.: A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120:679-684.
18. Deeg HJ, Jiang PY, Holmberg LA, et al.: Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004, 28:1177-1180.
19. Sloand EM, Greenberg P, Wu C, et al.: Immunosuppressive treatment is associated with durable responses and a survival advantage in younger patients with int-1 myelodysplastic syndrome [abstract]. Blood 2005, 106(Suppl 1). Abstract 2519.
20. Melchert M, Kale V, List A: The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 2007, 14:123-129.
21. Saunthararajah Y, Nakamura R, Nam JM, et al.: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
22. Saunthararajah Y, Nakamura R, Wesley R, et al.: A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102:3025-3027.
23. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
24. Barrett AJ, Savani BN: Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2007, In press.
25. Barrett AJ, Rezvani K: Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 2007, 148:189-198. A review of recent laboratory and clinical studies of peptide vaccines in myeloid malignancies including MDS.
26. Rezvani K, Yong A, Mielke S, et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2007, In press.